Annals of Surgical Oncology

, Volume 24, Issue 12, pp 3647–3657 | Cite as

Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer

  • V. K. Y. Ho
  • E. P. M. Jansen
  • B. P. L. Wijnhoven
  • K. J. Neelis
  • J. W. van Sandick
  • R. H. A. Verhoeven
  • V. E. P. Lemmens
  • H. W. M. van Laarhoven
Gastrointestinal Oncology

Abstract

Background

While the curative approach to gastric cancer includes perioperative regimens in several countries, a substantial proportion of patients may not receive treatment prior to surgery. This study examines the adjuvant provision of chemoradiotherapy (CRT) for non-pretreated patients with cancer of the stomach including the gastric cardia.

Methods

All surgically treated patients with primary adenocarcinoma of the stomach and gastric cardia diagnosed between January 2004–December 2013 were selected from the Netherlands Cancer Registry. Patients who did not receive neoadjuvant treatment were included. Early gastric cancers (cT1), postoperative deaths within 90 days, patients with metastatic disease (M1), patients who received adjuvant chemotherapy and patients with macroscopic tumor after surgery (R2) were excluded.

Results

Some 3277 patients underwent surgery, and 99 patients (3%) received adjuvant CRT. Treatment was more often administered in patients with a younger age (<65 years) and a high socioeconomic status (SES), in case of non-cardia cancer, positive lymph nodes, and positive resection margins (R1). Median survival time was 28 months (95% CI 17–39), compared to 35 months (95% CI 33–38) in CRT-naïve patients. After adjustment for confounders, a small net benefit for adjuvant CRT was found (hazard ratio, HR: 0.75, 95% CI 0.58–0.96). In subgroup analyses, benefit was most pronounced for patients with seven or more lymph metastases.

Conclusions

Marginal survival benefit was observed for adjuvant CRT in gastric cancer patients who did not receive neoadjuvant treatment. Treatment could be considered for patients with disease involving nodal invasion and those left with microscopic residual disease after surgery.

Notes

Acknowledgement

The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for collecting data in the Netherlands Cancer Registry (NCR).

Disclosure

None declared.

Compliance with Ethical Standards

Ethical Approval

All procedures followed were in accordance with the ethical standards of the national supervisory committee of the Netherlands Cancer Registry (NCR) and with the Helsinki Declaration of 1964 and later versions.

Informed Consent

Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi57–63.Google Scholar
  7. 7.
    Ho VK, Damhuis RA, Hartgrink HH. Adherence to national guidelines for gastric cancer in the Netherlands: a retrospective population-based audit. Int. J. Cancer. Journal international du cancer. 2013;132(5):1156–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Soon YY, Leong CN, Tey JC, Tham IW, Lu JJ. Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2014;58(4):483–96.PubMedGoogle Scholar
  10. 10.
    Dai Q, Jiang L, Lin RJ, Wei KK, Gan LL, Deng CH, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology 2014;86(2):79–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Seyedin S, Wang PC, Zhang Q, Lee P. Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: a SEER population analysis. gastrointestinal cancer research: GCR. 2014;7(3–4):82–90.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Katz MS, Earle CC, et al. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer. 2012;118(1):248–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Kofoed SC, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scandinavian J Surg. 2012;101(1):26–31.Google Scholar
  15. 15.
    Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol. 2000;11(7):837–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35(7):1059–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Stiekema J, Trip AK, Jansen EP, Aarts MJ, Boot H, Cats A, et al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. Ann Surg Oncol. 2015;22(2):581–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Jacome AA, Wohnrath DR, Scapulatempo Neto C, Fregnani JH, Quinto AL, Oliveira AT, et al. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer. 2013;16(2):233–8.Google Scholar
  20. 20.
    Strauss J, Hershman DL, Buono D, McBride R, Clark-Garvey S, Woodhouse SA, et al. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys. 2010;76(5):1404–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. ICD-O international classification of diseases for oncology. Geneva: World Health Organization; 2000.Google Scholar
  22. 22.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. international union against cancer (UICC). Chichester: Wiley-Blackwell; 2010.Google Scholar
  23. 23.
    Sobin LH, Wittekind C. TNM classification of malignant tumours. International Union Against Cancer (UICC). New York: Wiley-Liss; 2002.Google Scholar
  24. 24.
    Tesser PTM, van Praag CS, van Dugteren FA, Herweijer LJ, van der Wouden HC. Rapportage minderheden 1995: concentratie en segregatie. Rijswijk: Sociaal en Cultureel Planbureau, 1995.Google Scholar
  25. 25.
    Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ (Clinical research ed). 2010;340:b5087.CrossRefGoogle Scholar
  26. 26.
    Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides G, Fields RC, et al. Prognostic performance of different lymph node staging systems after curative intent resection for gastric adenocarcinoma. Ann Surg. 2015;262(6):991–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: east vs. west. J Gastric Cancer. 2012;12(2):55–62.CrossRefPubMedGoogle Scholar
  28. 28.
    Enestvedt CK, Diggs BS, Shipley DK, Thomas CR, Billingsley KG. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointest Cancer Res: GCR. 2009;3(6):233–8.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Snyder RA, Castaldo ET, Bailey CE, Phillips SE, Chakravarthy AB, Merchant NB. Survival benefit of adjuvant radiation therapy for gastric cancer following gastrectomy and extended lymphadenectomy. Int J Surg Oncol. 2012;2012:307670.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279–85.CrossRefPubMedGoogle Scholar
  31. 31.
    Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 1999;35(4):558–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30(6):643–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    van de Poll-Franse LV, Lemmens VE, Roukema JA, Coebergh JW, Nieuwenhuijzen GA. Impact of concentration of oesophageal and gastric cardia cancer surgery on long-term population-based survival. Brit J Surg. 2011;98(7):956–63.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • V. K. Y. Ho
    • 1
  • E. P. M. Jansen
    • 2
  • B. P. L. Wijnhoven
    • 3
  • K. J. Neelis
    • 4
  • J. W. van Sandick
    • 5
  • R. H. A. Verhoeven
    • 1
  • V. E. P. Lemmens
    • 1
    • 6
  • H. W. M. van Laarhoven
    • 7
  1. 1.Departments of Registry and ResearchNetherlands Comprehensive Cancer Organization (IKNL)UtrechtThe Netherlands
  2. 2.Department of RadiotherapyAntoni van Leeuwenhoek Hospital/Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of SurgeryErasmus University Medical CenterRotterdamThe Netherlands
  4. 4.Department of RadiotherapyLeiden University Medical CenterLeidenThe Netherlands
  5. 5.Department of SurgeryAntoni van Leeuwenhoek Hospital/Netherlands Cancer InstituteAmsterdamThe Netherlands
  6. 6.Department of Public HealthErasmus University Medical CenterRotterdamThe Netherlands
  7. 7.Department of Medical OncologyAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations